Le Lézard
Classified in: Health, Business
Subjects: TNM, ACC

AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue


NORTH CHICAGO, Ill., July 24, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of July 22, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,481,177 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on July 22, 2019, there were outstanding 6,839,586 options to purchase shares of common stock (the "Stock Options"), 7,968,197 restricted stock units (the "Restricted Stock Units") and 2,388,508 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

 

SOURCE AbbVie


These press releases may also interest you

at 09:15
Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced the appointment of two key executives, Jeron Evans as Chief Revenue...

at 09:10
BioSkryb Genomics, a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer...

at 09:07
KURU® Footwear, the inventor of heel-first footwear, today unveiled its 2024 Foot Pain Trends Report. Featuring significant industry discoveries and valuable consumer perspectives, KURU's comprehensive and medically reviewed report highlights the...

at 09:05
Personalis, Inc. , a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company's NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA...

at 09:05
...

at 09:04
Canadian-based Noze, a global leader in the breath-based diagnostic space, announced today it received a new grant from the Bill & Melinda Gates Foundation, bringing the foundation's total grant funding to Noze to $1.8 million. The announcement comes...



News published on and distributed by: